ClinicalTrials.Veeva

Menu

Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)

ResMed logo

ResMed

Status

Completed

Conditions

Obstructive Sleep Apnea

Treatments

Device: ApneaLink Sleep Screener

Study type

Observational

Funder types

Industry

Identifiers

NCT00354614
CA-09-05

Details and patient eligibility

About

The primary endpoints for this study are that the AL validation will 1) achieve a sensitivity of greater than 80% for AHI values greater than or equal to 15, and 2) demonstrate a correlation coefficient of r=0.75 indicating strong correlation between the AHI of diagnostic PSG and AL.

Full description

All subjects with suspected Sleep Disordered Breathing (SDB) scheduled for diagnostic polysomnography (PSG) will be invited to participate in the study to be tested to determine if they have Sleep Disordered Breathing (SDB), using the ApneaLink (AL) Sleep Screener. Subjects initially will be tested for SDB in the home environment. Following an AL home test, subjects will undergo a simultaneous, attended diagnostic polysomnography (PSG) sleep study and ApneaLink test for the purpose of confirming and comparing the results between diagnostic PSG and the AL device.

Enrollment

81 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult subjects ( greater than 18 years of age) of either gender or any race
  • Suspected sleep disordered breathing
  • Untreated sleep disordered breathing
  • Willingness to use AL at home within 2 days of receipt and instruction on the AL
  • Willingness to use AL at home and undergo PSG within 2 to 4 weeks of completing the at home AL test

Exclusion criteria

  • Any subject requiring home oxygen therapy
  • Any subject currently receiving positive airway pressure therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems